- Home
- OXM vs NMRA Comparison
OXM vs NMRA Comparison
Compare OXM & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXM | NMRA |
|---|---|---|
| Founded | 1942 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.1M | 554.0M |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | OXM | NMRA |
|---|---|---|
| Price | $45.59 | $2.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $34.25 | $7.50 |
| AVG Volume (30 Days) | 359.7K | ★ 1.3M |
| Earning Date | 06-10-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,477,834,000.00 | N/A |
| Revenue This Year | $2.85 | N/A |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.57 | $0.63 |
| 52 Week High | $56.90 | $3.65 |
Technical Indicators
Market Signals| Indicator | OXM | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 71.13 | 45.31 |
| Support Level | $35.27 | $2.10 |
| Resistance Level | $47.89 | $2.22 |
| Average True Range (ATR) | 1.79 | 0.15 |
| MACD | 0.73 | 0.03 |
| Stochastic Oscillator | 98.60 | 73.26 |
Price Performance
Historical ComparisonAbout OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.